



## ***Neisseria meningitidis*, *Streptococcus pneumoniae* and *Haemophilus influenzae*: Three Major Causes of Bacterial Meningitis: Antibiotic Treatment, Sequelae and Microbial Resistance**

Guest Editors:

**Dr. Athanasia Xirogianni**

National Meningitis Reference Laboratory, Department of Public Health Policy, School of Public Health, University of West Attica, 11521 Athens, Greece

**Prof. Dr. Georgina Tzanakaki**

National Meningitis Reference Laboratory, Department of Public Health Policy, School of Public Health, University of West Attica, Athens, Greece

Deadline for manuscript submissions:  
**closed (31 October 2023)**

### **Message from the Guest Editors**

*Neisseria meningitidis*, *Streptococcus pneumoniae* and *Haemophilus influenzae* are the major causes of bacterial meningitis worldwide.

During the last years, there is a worldwide increasing concern about antibiotic use and the potential consequences, such as the development of microbial resistance against multi-used antibiotics. As a result, data obtained from local microbial resistance rates research, come to add important information for the therapy that should be used. In some cases, a change in the treatment regimen might be essential or the use of alternative antibiotics. In combination with the other factors discussed above, new therapeutic approaches are proposed for a better outcome.

This Special Issue will publish papers discussing the treatment against meningitis due to *N.meningitidis*, *S. pneumoniae* or *H.influenzae*, as well as antibiotic resistance.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi